摘要
结直肠癌(CRC)是全球范围内癌症相关死亡的主要原因之一.识别高复发及预后不良风险的患者对指导治疗策略至关重要.炎症相关生物标志物如中性粒细胞与淋巴细胞比值(NLR)、淋巴细胞与C反应蛋白比值(LCR)、血小板与淋巴细胞比值(PLR)、淋巴细胞与单核细胞比值(LMR)、C反应蛋白与白蛋白比值(CAR)已显示预测多种癌症预后的临床应用价值.此外,格拉斯哥预后评分(GPS)、全身炎症评分(SIS)和预后营养指数(PNI)、预后免疫和营养指数(PIN1)等基于循环血细胞计数和白蛋白浓度的评分系统也用于预测癌症预后.本文概述了这些炎症相关标志物在预测CRC预后中的作用,旨在为优化预后预测和治疗决策提供参考.
Abstract
Colorectal cancer(CRC)is one of the leading causes of cancer-related deaths worldwide.Identif-ying patients at high risk of recurrence and poor prognosis is essential to guide treatment strategies.Inflammation-relat-ed biomarkers such as neutrophil-to-lymphocyte ratio(NLR),lymphocyte-to-C-reactive protein ratio(LCR),platelet-to-lymphocyte ratio(PLR),lymphocyte-to-monocyte ratio(LMR),and C-reactive protein-to-albumin ratio(CAR)have demonstrated the value of predicting the prognosis of a wide range of cancers for clinical applications.In addition,Glasgow Prognostic Score(GPS),Systemic Inflammation Score(SIS),and Prognostic Nutritional Index(PNI),Prog-nostic Immunity and Nutritional Index(PINI),which are scoring systems based on circulating blood counts and albu-min concentrations,have been used to predict cancer prognosis.This article outlines the role of these inflammation-re-lated markers in predicting CRC prognosis,with the aim of informing optimized prognostic prediction and therapeutic decision-making.
NETL
NSTL
万方数据